Bajaj Healthcare Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Bajaj Healthcare Ltd is ₹ 284.95 as of 15 May 15:30 . The P/E Ratio of Bajaj Healthcare Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Bajaj Healthcare Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Bajaj Healthcare Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Bajaj Healthcare Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Bajaj Healthcare Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Bajaj Healthcare Ltd changed from 4.57 % to 7.99 % over 5 quarters. This represents a CAGR of 56.35% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Bajaj Healthcare Ltd

Incorporated in 1993, Maharashtra-based Bajaj Healthcare Limited is one of India's large scale and vertically integrated pharmaceutical manufacturer for quality-conscious customers.
The Company is engaged in the manufacturing and exporting of Active Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals. Company commenced its operations in 1993 with a single unit at Tarapur.
It became a public company in 2005 and listed its shares in the Indian stock exchanges in 2016. With Headquartered in Thane, Company has established 3 API plants in Gujarat and Maharashtra.
It has 4 units for APIs/ intermediates and one unit for formulation, which are designed to meet the requirements of both advanced as well as emerging market opportunities.
In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Bajaj Healthcare Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Bajaj Healthcare Ltd or Sanofi India Ltd?

Market cap of Bajaj Healthcare Ltd is 959 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Bajaj Healthcare Ltd and Sanofi India Ltd?

The stock performance of Bajaj Healthcare Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bajaj Healthcare Ltd and Sanofi India Ltd?

As of May 18, 2026, the Bajaj Healthcare Ltd stock price is INR ₹284.95. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Bajaj Healthcare Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Bajaj Healthcare Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.